ClinicalTrials.gg
Status unknownNCT04801667TXCoronavacUpdated Mar 18, 2022

Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients

A Phase 4 interventional study of Coronavac in SARS-CoV Infection, Coronavirus Infection and Vaccine Adverse Reaction, sponsored by Hospital do Rim e Hipertensão. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by Hospital do Rim e Hipertensão · Phase 4, Interventional, and Health services research

How we know

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,371
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil — 3 open to participants now, 4 under way, 2 of them phase 3. Severe Acute Respiratory Syndrome · Brazil.

Enrollment
5th of 26
3,371 · median 279
Started
2021
with 7 others
Phase 4
Only one
of the 29
Registered
24th of 29
by date

Among the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2021, is the only one in phase 4, and was the 24th registered.

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

Browse Severe Acute Respiratory Syndrome studies →

Open to participants now

3 of the 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Severe Acute Respiratory Syndrome with a site in Brazil, or all of them as a file.
02

Study summary

Since the beginning of the SARS-CoV-2 pandemic, 1031 (8.7%) of the 11875 kidney transplant recipients being followed up at Hospital do Rim have been infected. The overall lethality rate was 24%, reaching 53% among those over 70 years old. Among the survivors, there is also a high incidence of renal dysfunction with loss of the renal graft and definitive return to dialysis. Patients receiving pharmacological immunosuppression, including transplant recipients, have not been included in the studies carried out to date. In addition, kidney transplant recipients may have reduced vaccine responses compared to the general population. The severity, the high incidence of renal dysfunction and loss of renal graft, and the high lethality associated with COVD-19 justify the investigation of the epidemiological impact and immunogenicity of the vaccine against SARS-CoV-2 infection.

03

Conditions studied

  • SARS-CoV Infection
  • Coronavirus Infection
  • Vaccine Adverse Reaction
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults over 18 years old;
  2. Time after transplantation greater than 3 months;
  3. Time after treatment with anti-thymocyte globulin longer than 4 weeks;
  4. Able and willing (in the investigator's opinion) to comply with all study requirements;
  5. Provide written

Exclusion criteria

Exclusion Criteria:

  1. Planned receipt of any vaccine (authorized or experimental), within 30 days before and after vaccination;
  2. Prior receipt of an experimental or authorized vaccine with the possibility of impacting the interpretation of the study data (for example, vectorized vaccines by Adenovirus, any vaccines against coronavirus);
  3. Administration of immunoglobulins and / or any blood products in the three months prior to the planned administration of the candidate vaccine;
  4. Any history of angioedema or anaphylaxis;
  5. Pregnancy, lactation or willingness / intention to become pregnant during the study;
  6. Diagnosis or current treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ);
  7. History of severe psychiatric illness that possibly affects your participation in the study;
  8. Hemorrhagic disorder (eg, factor deficiency, coagulopathy or disorder) or a previous history of significant bleeding or hematoma after IM injections or venipuncture;
  9. Continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban);
  10. Current suspected or known addiction to alcohol or drugs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,371 participants (actual)

Study arms

  • Experimental
    Coronavac vaccine

    Kidney transplant recipients receiving the coronavac vaccine

    Biological: Coronavac

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the incidence of hospitalization or death in 28 days associated with COVID-19 (symptomatic cases confirmed virologically by COVID -19 with positive CRP) 14 ± 2 days after the second dose of the vaccine.

    Time frame: 45 days

Secondary outcomes

  1. Evaluate the impact of the vaccine on the incidence of COVID-19 according to the severity criterion of the World Health Organization.

    Time frame: 6 months

  2. Evaluate the impact of the vaccine on the incidence of COVID-19 and hospitalization for COVID-19 disease, confirmed by PCR, for a period of 6 months after the final vaccination.

    Time frame: 6 months

  3. Evaluate the vaccine's safety, tolerability, and reactogenicity profile: occurrence of signs and symptoms of local and systemic reactogenicity requested seven days after vaccination.

    Time frame: 7 days

  4. Evaluate the incidence of serious adverse events for a period of 6 months after the final vaccination.

    Time frame: 6 months

  5. Evaluate immunogenicity by detecting antibodies against SARS-CoV-2 for a period of 6 months after the final vaccination.

    IgG antibody levels will be used to assess immunogenicity.

    Time frame: 6 months

  6. Analysis of the genetic sequencing of SARS-CoV-2 in patients who test positive for SARS-CoV-2 PCR.

    Genetic sequencing of the virus will be carried out, that is, reading the genome of Sars-Cov-2, to evaluate possible new variants.

    Time frame: 6 months

07

Study locations

1 site
  • Hospital do Rim - Fundação Oswaldo Ramos
    São Paulo, Brazil
08

References and documents

Publications

  • Medina-Pestana J, Covas DT, Viana LA, Dreige YC, Requiao-Moura LR, Nakamura MR, Lucena EF, Foresto RD, Tedesco-Silva H, Cristelli MP. Homologous Third Dose of Inactivated Whole-virion Vaccine Fails to Elicit a Robust Immune Response Among Kidney Seronegative Transplant Recipients. Transplantation. 2022 May 1;106(5):e284-e285. doi: 10.1097/TP.0000000000004029. Epub 2021 Dec 28. No abstract available. PubMed 34974453 ↗
  • Medina-Pestana J, Covas DT, Viana LA, Dreige YC, Nakamura MR, Lucena EF, Requiao-Moura LR, Fortaleza CMCB, Foresto RD, Tedesco-Silva H, Cristelli MP. Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results. Transplantation. 2022 Apr 1;106(4):853-861. doi: 10.1097/TP.0000000000004036. PubMed 34882589 ↗
  • Medina-Pestana J, Cristelli MP, Viana LA, Foresto RD, Requiao-Moura LR, Tedesco-Silva H, Covas DT. Clinical Impact, Reactogenicity, and Immunogenicity After the First CoronaVac Dose in Kidney Transplant Recipients. Transplantation. 2022 Jan 1;106(1):e95-e97. doi: 10.1097/TP.0000000000003901. No abstract available. PubMed 34292214 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Oct 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 17, 2021
StartActual
Mar 20, 2021
Primary completionActual
Oct 1, 2021
CompletionEst.
Mar 1, 2023
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04801667
Lead sponsor
Hospital do Rim e Hipertensão
Responsible party
Helio Tedesco Silva Junior (Affiliate teacher, Hospital do Rim e Hipertensão) — Principal investigator
First posted
Mar 17, 2021
Start date
Mar 20, 2021
Primary completion
Oct 1, 2021
Completion
Mar 1, 2023 (estimated)
Last update
Mar 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sinovac COVID-19 vaccine

Start the discussion